Salarius Pharmaceuticals Files S-1 for Potential Securities Offering

TL;DR

Salarius Pharma (SLRX) filed an S-1, looks like they're raising cash. Watch this space.

AI Summary

Salarius Pharmaceuticals, Inc. filed an S-1 registration statement on December 16, 2024, to register an unspecified number of securities. The company, formerly known as Flex Pharma, Inc. until July 30, 2014, is based in Houston, Texas, and operates in the pharmaceutical preparations sector. This filing indicates a potential offering of new shares or other securities to raise capital.

Why It Matters

This S-1 filing signals Salarius Pharmaceuticals' intent to raise capital, which could fund further research and development or expansion, potentially impacting its stock value and the availability of its pharmaceutical products.

Risk Assessment

Risk Level: medium — S-1 filings often precede capital raises, which can dilute existing shareholders or indicate financial needs, but the specific details of the offering are not yet disclosed.

Key Numbers

• 2834 — SIC Code (Pharmaceutical Preparations industry)
• 46-5087339 — IRS Number (Company's Employer Identification Number)

Key Players & Entities

• Salarius Pharmaceuticals, Inc. (company) — Registrant
• Flex Pharma, Inc. (company) — Former company name
• 20140730 (date) — Date of name change
• 20241216 (date) — Filing date
• David J. Arthur (person) — President and Chief Executive Officer
• Hogan Lovells US LLP (company) — Legal counsel

FAQ

Key Financial Figures

• $0.0001 — 3,334 shares of common stock, par value $0.0001 per share, or common stock. The shares
• $1.50 — uming the shares are sold at a price of $1.50 per share) and (ii) up to 66,667 shares
• $1 — ent Shares) is equal to or greater than $1.528, which is a price equal to the lowe
• $10.0 million — t Shares. However, we may receive up to $10.0 million in aggregate gross proceeds from the
• $1.44 — stock on The Nasdaq Capital Market was $1.44 per share. We are a "smaller reporting
• $10 million — ed to purchase, up to the lesser of (i) $10 million of newly issued shares (the "Purchase S
• $1.00 — mmon stock was equal to or greater than $1.00 (the "Purchase Date"), we may direct th
• $200,000 — tock (a "Fixed Purchase") not to exceed $200,000, at a purchase price equal to the lesse
• $2,500,000 — Selling Stockholder to us that exceeds $2,500,000, unless such limitation is waived by th
• $250 million — ock held by non-affiliates is less than $250 million as of June 30 of such fiscal year or (i
• $100 million — or (ii) our annual revenue is less than $100 million during the most recently completed fisc
• $700 million — ock held by non-affiliates is less than $700 million measured as of June 30 of such fiscal y

Filing Documents

• slrx-elocformsx1.htm (S-1) — 404KB
• slrx-ex107xfilingfeetabl.htm (EX-FILING FEES) — 3KB
• slrx-ex51xhlopinionelocsx1.htm (EX-5.1) — 14KB
• readonly-s1pgap05aconsentl.htm (EX-23.1) — 2KB
• image_0.jpg (GRAPHIC) — 22KB
• image_0a.jpg (GRAPHIC) — 0KB
• image_10.jpg (GRAPHIC) — 0KB
• image_2a.jpg (GRAPHIC) — 0KB
• image_8.jpg (GRAPHIC) — 0KB
• image_9a.jpg (GRAPHIC) — 46KB
• slrx-ex107xfilingfeetabl001.jpg (GRAPHIC) — 144KB
• 0001615219-24-000098.txt ( ) — 717KB

Risk Factors

Risk Factors 7 Special Note Regarding Forward-Looking Statements 14 The Committed Equity Financing 16

Use of Proceeds

Use of Proceeds 22 Market Information 23 Dividend Policy 24 Dilution 25 The Selling Stockholder 2 6

Description of Capital Stock

Description of Capital Stock 2 8 Plan of Distribution 3 1 Legal Matters 3 2 Experts 3 2 Where You Can Find Additional Information 3 3 Incorporation of Certain Information by Reference 3 4 ABOUT THIS PROSPECTUS The registration statement we filed with the Securities and Exchange Commission, or the SEC, includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus, the related exhibits filed with the SEC, and the documents incorporated by reference herein before making your investment decision. You should rely only on the information provided in this prospectus and the documents incorporated by reference herein or any amendment thereto. You should not assume that the information contained in this prospectus is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference herein or therein is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus is delivered, or securities are sold, on a later date. This prospectus contains or incorporates by reference summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed or have been or will be incorporated by reference as exhibits to the registration statement of which this prospectus forms a part, and you may obtain copies of those documents as described in this prospectus under the heading " Where You Can Find More Information ." You should rely only on the information that we have included or incorporated by reference in this prospectus. Neither we nor the Selling Stockholder has authorized any other person to provide you with different information. If anyone pro

View Full Filing

View this S-1 filing on SEC EDGAR